The NGR targeting domain, besides delivering TNF effector molecules to CD13-positive tumor vessels, can also induce co-signaling mechanisms that impair the activation of pro-survival pathways by the TNF moiety, a mechanism that may contribute to the biological effects observed with extremely low doses of the fusion protein. The gene discussed is RTN4R; the disease is neoplasm.